Leeds research could revolutionise vaccine development

Research which has identified a way of making a safer and cheaper polio vaccine is to be scaled-up – to see if it could be used in commercial vaccine production.

The new approach, which has the potential to revolutionise vaccine development across the board, is the result of a scientific collaboration led by the University.

It is based on a process using harmless proteins called virus-like particles (VLPs) rather than a live virus, which carries the risk of escaping and infecting people.

CPI, an innovation "catapult" that commercialises new technologies, has created a pilot-scale manufacturing platform using the method of vaccine manufacture developed in the Leeds laboratories. Read more.